InvestSMART

Imagion Biosystems Limited (ASX:IBX)

ALERT: Price-sensitive ASX Announcement for IBX
Current share price for IBX : $0.008 -0.003 (-27.27%)+
Announcement
Release
24 Aug 2026 5:51PM
Price at Release
$0.011
Full Release
download
Summary
Imagion Biosystems Limited reported a loss for the half-year ended 30 June 2026, with a loss increase of 19.2% from the previous period, primarily due to increased research and development expenses. The company's revenue and other income improved significantly, driven by a gain on modification of debt. Despite the financial losses, the directors are confident in the company's capacity to continue as a going concern, leveraging recent capital raisings and strategic management of research and development activities. The MagSense® imaging agent for HER2 breast cancer is being progressed towards Phase 2 clinical trials. Notably, the financial report highlights a material uncertainty regarding the company's ability to continue as a going concern due to ongoing losses and liabilities.
Key Points
  • Imagion Biosystems Limited reported a loss of $1,981,169 for the half-year ended 30 June 2026, an increase of 19.2% from the previous period.
  • There were no dividends declared during the current or previous financial periods.
  • Net tangible assets per ordinary security decreased to (0.63) cents as of 30 June 2026.
  • The financial report includes a material uncertainty related to going concern due to significant losses and net liabilities.
  • Revenue and other income increased to $525,934, primarily from a gain on modification of debt.
  • Research and development expenses increased significantly to $1,589,664.
  • The company issued new shares and performance rights, with various conditions tied to market capitalization achievements.
  • The directors believe the company will continue as a going concern due to recent capital raisings and financial strategies.
  • Imagion is advancing its MagSense® imaging agent candidate for HER2 breast cancer towards Phase 2 clinical trials.
  • The company continues to manage its financial position with a focus on strategic research and development activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.